The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
|Articles|December 8, 2013
Final Stage 2 Results of the CLL11 Trial
Author(s)Jennifer Brown, MD, PhD
Jennifer Brown, MD, PhD, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
Advertisement
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
- The CLL11 study provided the basis for the approval of GA101 (obinutuzumab)
- GA101 has a different mechanism than rituximab or ofatumumab in that it confers increased direct cell death
- GA101 + chlorambucil compared with chlorambucil alone now has demonstrated a statistically significant improvement in overall survival
- In the direct comparison, GA101 + chlorambucil demonstrated an improvement in progression-free survival compared with rituximab + chlorambucil (27 months vs 16 months)
- GA101 + chlorambucil also has demonstrated a higher complete remission rate and MRD negativity rate
<<<
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5